Results from EPD’s DURABLE-I clinical trial, whose principal investigator is Professor Evgeny A Pokushalov, were presented for the first time at the 2017 AF Symposium by Professor Karl-Heinz Kuck, Head of the Department of Cardiology at the Asklepios Klinik in Hamburg, Germany. The presentation, “DURABLE-I Study: Real-time gap detection during AF ablation using dielectric sensing”, […]Read Story
Tortola, April 28 2016 – EPD has completed its first human procedure, having successfully tested its revolutionary D700 Dielectric Sensing System at the Meshalkin State Research Institute of Circulation Pathology in Novosibirsk, Russia, headed by Professor Evgeny Pokushalov. The EPD D700 System employs dielectric sensing for guided personalized intra-cardiac navigation, and provides electrode-tissue contact quality, […]Read Story
Prof. Shlomo Ben-Haim, Founder of Hobart Group, authored “How Innovation Can Unleash Tremendous Growth in the $3.4 Billion AF Ablation Market”, published…Read Story
EPD will present its novel real-time D700 tissue characterization technology for permanent transmural ablation at the upcoming 13th International Dead Sea Symposium (IDSS)…Read Story
An editorial written by Mattias Duytschaever, Philippe Taghji and Rene Tavernier referring to the seminal paper ‘EFFICAS II: optimization of catheter…Read Story
EPD presented its proprietary catheter-based cardiac ablation platform in a private setting at the annual Heart Rhythm Society (HRS) conference in Boston…Read Story
Results from the Adenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination (ADVICE) trial were presented…Read Story
Atrial fibrillation (AF) is an abnormal heart rhythm which is characterized by irregular and rapid beating. As the most common arrhythmia, it affects about 3% of the population in North America and Europe and is the second leading cause of stroke.
EP Dynamics (EPD), a member of the Hobart Group companies, is dedicated to improving the efficacy and efficiency of minimally invasive catheter-based procedures performed to treat cardiac arrhythmias. EPD is developing a proprietary dielectric-based platform that enables the measurement of the permanency, transmurality and continuity of cardiac AF ablation lesions, thereby significantly improving the efficacy of AF ablation. The platform also provides an estimated ablation depth, reports catheter contact quality and gives an accurate 3D localization of EP catheters. For more information, please visit www.epd-medical.com.
The Hobart Group develops and commercializes medical technologies which target top healthcare markets with significant unmet needs. Its growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation. Together, Hobart Group companies have over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from clinical expertise and extensive regulatory and international market knowledge across Europe, the USA and Asia. For more information, visit www.Hobart-Group.com.